Sulfur In R Patents (Class 514/618)
-
Publication number: 20110306670Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.Type: ApplicationFiled: August 25, 2011Publication date: December 15, 2011Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventor: Heinz-Werner KLEEMANN
-
Publication number: 20110301235Abstract: Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein.Type: ApplicationFiled: December 2, 2010Publication date: December 8, 2011Applicant: Alquest Therapeutics, Inc.Inventors: Daniel A. Erlanson, Stig K. Hansen
-
Patent number: 8063026Abstract: Provided herein are methods of using mannan oligosaccharides, to treat, palliate, relieve, prevent and/or eliminate urinary tract infections of humans. A mixture of oligosaccharides derived from yeast cell walls is shown to reduce, eliminate and prevent the symptoms of UTI in patients.Type: GrantFiled: October 6, 2006Date of Patent: November 22, 2011Inventor: Richard Katz
-
Publication number: 20110281879Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: January 12, 2011Publication date: November 17, 2011Applicant: ViroBay, Inc.Inventor: Craig Mossman
-
Patent number: 8048222Abstract: The present invention provides an improved process for preparing modafinil, whereby it may be isolated in high purity by a single crystallization. The process produces modafinil free of sulphone products of over-oxidation and other byproducts. The invention further provides new crystalline Forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil Forms II-IV and VI.Type: GrantFiled: September 23, 2004Date of Patent: November 1, 2011Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Arina Ceausu, Anita Lieberman, Judith Aronhime
-
Patent number: 8044048Abstract: Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.Type: GrantFiled: January 4, 2007Date of Patent: October 25, 2011Assignee: Southern Research InstituteInventors: Gary Piazza, Robert Reynolds
-
Patent number: 8034845Abstract: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.Type: GrantFiled: May 28, 2004Date of Patent: October 11, 2011Assignee: Intervet Inc.Inventors: Keith A. Freehauf, Allan Weingarten, Robert D. Simmons, Kanwal Jit Varma
-
Publication number: 20110245336Abstract: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.Type: ApplicationFiled: June 13, 2011Publication date: October 6, 2011Inventors: Tong Sun, David Jonaitis, Stephan D. Parent
-
Publication number: 20110245262Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: August 20, 2007Publication date: October 6, 2011Inventors: Lijun Sun, Keizo Koya, Shoujun Chen, Zachary Demko, Zhi-Qiang Xia
-
Publication number: 20110237525Abstract: A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.Type: ApplicationFiled: June 18, 2010Publication date: September 29, 2011Inventors: Boyd E. Haley, Niladri Narayan Gupta
-
Publication number: 20110236395Abstract: Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag.Type: ApplicationFiled: September 9, 2009Publication date: September 29, 2011Applicant: UNIVERSITY OF EAST ANGLIAInventors: Ian Michael Wormstone, Lucy Dawes, Julie Ann Eldred, Dylan Edwards, Lisa Hodgkinson
-
Publication number: 20110230563Abstract: Novel amidoacetonitrile compounds are disclosed. The compounds have pesticidal properties and are suitable for controlling endoparasites on warm-blooded animals.Type: ApplicationFiled: December 2, 2009Publication date: September 22, 2011Inventors: Noëlle Gauvry, Thomas Goebel
-
Publication number: 20110229578Abstract: The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 ?m in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof.Type: ApplicationFiled: April 26, 2011Publication date: September 22, 2011Applicant: CEPHALON FRANCEInventors: Thanh-Tam Nguyen, Joëolle Leyder
-
Publication number: 20110224196Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine.Type: ApplicationFiled: January 7, 2011Publication date: September 15, 2011Applicant: Vivus, Inc.Inventors: Leland F. Wilson, Peter Tam, Thomas Najarian, Charles H. Bowden
-
Publication number: 20110206744Abstract: The invention provides an oral pharmaceutical composition comprising modafinil particles, wherein at least about 5% of said modafinil particles have a diameter greater than 200 microns.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Applicant: CEPHALON, INC.Inventors: Moshe Bentolila, Aldo Shusterman, Moshe Arkin, Joseph Kaspi
-
Patent number: 7998971Abstract: The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.Type: GrantFiled: June 21, 2007Date of Patent: August 16, 2011Assignee: BrainCells Inc.Inventors: Carrolee Barlow, Todd A. Carter, Andrew Morse, Kai Treuner, Kym I. Lorrain
-
Patent number: 7994223Abstract: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.Type: GrantFiled: July 22, 2010Date of Patent: August 9, 2011Assignee: Abbott LaboratoriesInventors: Michael R. Schrimpf, Kathleen H. Mortell, Diana L. Nersesian, Chih-Hung Lee, Bruce Clapham
-
Publication number: 20110165259Abstract: [Problem to be Solved] The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. [Solution] A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: September 15, 2009Publication date: July 7, 2011Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi Hirokawa, Takahiro Tada, Jun Nihira
-
Publication number: 20110159054Abstract: The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer.Type: ApplicationFiled: March 2, 2011Publication date: June 30, 2011Inventors: Scott Jenkins, Gary Liversidge
-
Publication number: 20110136832Abstract: Cycling of ApoE4 isoform is promoted in a person in need thereof by contacting the person with an effective amount of a pharmaceutically-acceptable modulator of intracellular ApoE4 transport vesicle pH.Type: ApplicationFiled: December 7, 2010Publication date: June 9, 2011Inventors: Joachim Herz, Xunde Xian, Yuan Yang
-
Publication number: 20110129519Abstract: Methods and compositions comprising modafinil are described for treating premature ejaculation in a male individual.Type: ApplicationFiled: February 7, 2011Publication date: June 2, 2011Inventor: Daniel E. Katzman
-
Publication number: 20110091405Abstract: Compositions, kits and methods are provided for conditioning, revitalizing, volumizing or increasing the natural pigmentation of the hair, including hair on the scalp, eyelashes, eyebrows, mustache and beard, promoting healthy growth, and treating and preventing loss, thinning or miniaturization of hair due to aging, various genetic, pathological, radiation, chemotherapy, chemical treatment, environmental or other reasons.Type: ApplicationFiled: October 27, 2010Publication date: April 21, 2011Applicant: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Patent number: 7915252Abstract: Sulfonyl derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM.Type: GrantFiled: August 3, 2005Date of Patent: March 29, 2011Assignee: Merck Sharp & DohmeInventors: Sherman T. Waddell, James M. Balkovec, Gina M. Santorelli, Aaron H. Leeman, Milana Maletic, Xin Gu
-
Publication number: 20110065681Abstract: Compounds are provided according to formula 1: where A, B, W, X?, L, R1, R3, R4b, and m? are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.Type: ApplicationFiled: February 27, 2009Publication date: March 17, 2011Inventors: Zhi-Liang Wei, Sumithra Gowlugari, Carl Kaub, Zhan Wang, Yeyu Cao, John Kincaid
-
Publication number: 20110065799Abstract: The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.Type: ApplicationFiled: November 22, 2010Publication date: March 17, 2011Applicant: The Medicines Company (Leipzig) GmbHInventors: Jörg Stürzebecher, Torsten Steinmetzer, Andrea Schweinitz
-
Patent number: 7902372Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.Type: GrantFiled: April 2, 2008Date of Patent: March 8, 2011Assignee: Eli Lilly and CompanyInventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
-
Patent number: 7893092Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I) can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: December 7, 2005Date of Patent: February 22, 2011Assignee: Syngenta Crop Protection, Inc.Inventors: Andre Jeanguenat, Anthony Cornelius O'Sullivan
-
Patent number: 7893111Abstract: The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I). wherein Ar, Y, R1 are as defined in claim 1.Type: GrantFiled: March 13, 2006Date of Patent: February 22, 2011Assignee: Cephalon FranceInventors: Laurence Prat, Olivier Neckebrock
-
Patent number: 7893093Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: March 22, 2006Date of Patent: February 22, 2011Assignee: ViroBay, Inc.Inventor: Craig J. Mossman
-
Publication number: 20110033506Abstract: Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating.Type: ApplicationFiled: February 8, 2009Publication date: February 10, 2011Inventors: Adel Penhasi, Janina Gauchman, Amanda Shauli, Marina Ruderman, Avi Avramoff
-
Patent number: 7884135Abstract: Methods and compositions comprising modafinil are described for treating premature ejaculation in a male individual.Type: GrantFiled: August 13, 2007Date of Patent: February 8, 2011Assignee: NeuroHealing Pharmaceuticals, Inc.Inventor: Daniel E. Katzman
-
Publication number: 20110008258Abstract: Methods for treating breathing disorders by inhibition of the induced PGE2 pathway in a mammalian subject, methods for assessing apnea, hypoxic ischemic encephalopathy or perinatal asphyxia by detecting an elevated level of PGE2, or a metabolite thereof, in a sample from the subject compared with a control level, and in vitro and in vivo screening methods for medicaments for treating breathing disorders are disclosed.Type: ApplicationFiled: November 12, 2008Publication date: January 13, 2011Applicant: SAMSARA MEDICIN ABInventors: Eric Herlenius, Per-Johan Jakobsson, Annika Hofstetter Olsson
-
Publication number: 20110003852Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: February 18, 2008Publication date: January 6, 2011Inventor: Soren Ebdrup
-
Publication number: 20100331418Abstract: Disclosed herein are novel antagonists of the androgen receptor and androgen receptor mutations associated with clinical failure of currently prescribed anti-androgens and use of said antagonists in the treatment of conditions associated with inappropriate activation of the androgen receptor.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Inventors: John Tze-tzun KOH, Paula Lynn McGinley, Hongmu Pan, Robert Sikes
-
Publication number: 20100324146Abstract: The present invention relates generally to the use of dendrimer compounds bearing anionic surface groups as inhibitors of hyaluronidase and their use in the treatment of diseases and conditions in which excessive, abnormal or unwanted levels of hyaluronidase are involved or implicated, or in the treatment of diseases or conditions in which the presence or administration of hyaluronic acid is therapeutically effective. The present invention also relates to pharmaceutical compositions and methods for the treatment of such diseases and conditions.Type: ApplicationFiled: February 20, 2009Publication date: December 23, 2010Applicant: Starpharma Pty LtdInventor: Jacinth Kincaid Fairley
-
Publication number: 20100311701Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicants: Transform Pharmaceuticals, Inc, University Of South Florida, The Regents of the University Of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20100305056Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: November 26, 2008Publication date: December 2, 2010Applicant: Merck Frosst Canada Ltd.Inventors: Elise Isabel, Christophe Mellon, Christian Beaulieu
-
Publication number: 20100286109Abstract: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.Type: ApplicationFiled: July 22, 2010Publication date: November 11, 2010Applicant: ABBOTT LABORATORIESInventors: Michael R. Schrimpf, Kathleen H. Mortell, Diana L. Nersesian, Chih-Hung Lee, Bruce Clapham
-
Publication number: 20100286125Abstract: Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are useful in the treatment of poisoning by anthrax.Type: ApplicationFiled: March 28, 2008Publication date: November 11, 2010Inventors: Alan T. Johnson, Seongjin Kim
-
Publication number: 20100280113Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: July 14, 2010Publication date: November 4, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Publication number: 20100267835Abstract: Alpha-aminoamide derivatives useful in the treatment of disorders of trigeminalvascular activation are disclosed.Type: ApplicationFiled: January 15, 2010Publication date: October 21, 2010Applicant: Newron Pharmaceuticals SpAInventors: Patricia Salvati, Marcello Calabresi, Luciano Dho, Orietta Veneroni, Piero Melloni
-
Publication number: 20100249147Abstract: [Problem] To provide a compound that is useful as an agent in the prevention and treatment of circulatory system, nervous system, metabolic, reproductive system, and gastrointestinal diseases. [Means for Resolution] A compound or a pharmaceutically acceptable salt thereof represented by the following Formula (I): [wherein, Z represents formula (II-1), (II-2), or (II-3), wherein m and n are 0, 1, or 2, Y represents CR3 or N, R1 represents a C1-6 alkyl, C3-8 cycloalkyl, etc., R2 represents phenyl or a heteroaryl, etc., R3 and R4 each independently represent a hydrogen atom, a C1-6 alkyl, etc., M1, M2, M3, and M4 each independently represent a hydrogen atom, a C1-6 alkyl, etc.Type: ApplicationFiled: December 16, 2008Publication date: September 30, 2010Inventors: Tsuyoshi Nagase, Takahide Sasaki, Toshiyuki Takahashi
-
Publication number: 20100234468Abstract: The present invention relates to a process for the preparation of polymorphic forms of the R- and S-enantiomers of modafinil, R-(?)-2-benzhydrylsulfinylacetamide and S-(+)-2-benzhydrylsulfinylacetamide respectively.Type: ApplicationFiled: May 30, 2008Publication date: September 16, 2010Inventors: Abhay Gaitonde, Bindu Manojkumar, Sandeep Mekde, Dattatrey Kokane
-
Patent number: 7786171Abstract: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.Type: GrantFiled: March 26, 2009Date of Patent: August 31, 2010Assignee: Abbott LaboratoriesInventors: Michael R. Schrimpf, Kathleen H. Mortell, Diana L. Nersesian, Chih-Hung Lee, Bruce Clapham
-
Publication number: 20100209495Abstract: A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate.Type: ApplicationFiled: September 16, 2009Publication date: August 19, 2010Applicant: Mylan Laboratories, Inc.Inventors: Boyong LI, Thomas Daniel Reynolds
-
Publication number: 20100210731Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: ApplicationFiled: February 19, 2010Publication date: August 19, 2010Applicant: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20100210631Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases.Type: ApplicationFiled: May 14, 2008Publication date: August 19, 2010Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
-
Publication number: 20100204334Abstract: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.Type: ApplicationFiled: February 6, 2009Publication date: August 12, 2010Inventors: Mary Ann Katherine Greco, William Howard Frey, II, Jacqueline DeRose, Rachel Beth Matthews, Leah Ranae Bresin Hanson
-
Publication number: 20100197794Abstract: There is provided a fluorine-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein G represents an oxygen atom or a sulfur atom; R2 represents a C1-C4 chain hydrocarbon group which is optionally substituted with a halogen atom, etc.; R3 and R4 independently represent a C1-C4 chain hydrocarbon group or a hydrogen atom; R represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom; R6 represents a halogen atom, a cyano group, a nitro group or a -(G)q-R8 group; R7 represents an amino group etc.; R8 represents a C1-C4 chain hydrocarbon group which is optionally substituted with a halogen atom; m represents an integer of 0 to 5; n represents an integer of 0 to 2; p represents 0 or 1; q represents 0 or 1; and G1 represents an oxygen atom etc.Type: ApplicationFiled: July 25, 2008Publication date: August 5, 2010Inventors: Koji Kumamoto, Hiroyuki Miyazaki
-
Publication number: 20100189683Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Ascenta Therapeutics, Inc.Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang